What Is Next For Ophthotech (OPHT) After Failed Phase 3 Trial?

OPHT, REGN

We listened to the conference call by Ophthotech (OPHT) management (link). The results of the phase 3 trial were shocking to many investors since the phase 2b study showed a clear significant benefit for Fovista+Lucentis combination (with shorter duration of treatment). Link to press release.

In t...

We listened to the conference call by Ophthotech (OPHT) management (link). The results of the phase 3 trial were shocking to many investors since the phase 2b study showed a clear significant benefit for Fovista+Lucentis combination (with shorter duration of treatment). Link to press release.

In t...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics